Kindeva has confirmed a major leadership change as it moves to accelerate growth across its parenteral and inhaled drug delivery businesses.

 

The global contract development and manufacturing organization (CDMO) announced that David Stevens has assumed the role of Chief Executive Officer, effective January 1, 2026. Stevens, who previously served as President, steps into the top role as the company sharpens its focus on expansion, innovation, and customer partnerships.

 

Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors, ensuring continuity and strategic oversight.

 

“I am deeply honored to have the opportunity to succeed Milton as Kindeva's Chief Executive Officer and look forward to building on his success. Kindeva's unique heritage of innovation, industry leading capabilities, and our dedicated expert employees, means we have an exciting future ahead,” said David Stevens, CEO of Kindeva. 

 

“Our focus remains on driving growth and performance by offering best-in-class drug delivery solutions while continuing to provide exceptional service and reliability for our customers. I feel incredibly privileged to lead Kindeva into this next chapter and work alongside our talented team to achieve our ambitious goals.”

 

Kindeva said Stevens brings a strong track record of leading organizations through periods of rapid growth and capacity expansion, positioning the company to scale its core drug delivery platforms and strengthen customer relationships.

 

George Aitken-Davies, co-founder and Managing Director at Altaris, welcomed the appointment and paid tribute to Boyer’s leadership.

 

“Kindeva has made significant progress in building a strong foundation for growth. Under David's leadership, we are well-positioned to execute our strategy and deliver value for customers, employees, and stakeholders. We thank Milton for his innumerable contributions as CEO, and look forward to his ongoing involvement at the Board level,” he said.

 

The leadership changes complete a succession plan launched in October 2025 and signal Kindeva’s emphasis on stability, continuity, and long-term growth as it enters its next phase.